J&J Says HHS Is Thwarting Transparency Of Drug Discounts

By Lauren Berg · November 12, 2024, 8:41 PM EST

Johnson & Johnson claims the U.S. Department of Health and Human Services is thwarting its efforts to crack down on hospitals the company alleges are "reaping immense profits" on reduced-price medications...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

JOHNSON & JOHNSON HEALTH CARE SYSTEMS INC. v. BECERRA et al

Case Number

Court

District Of Columbia

Nature of Suit

Administrative Procedure Act/Review or Appeal of Agency Decision

Date Filed

November 12, 2024

Recent Articles By Lauren

November 15, 2024
Eli Lilly Says HHS Ignores Drug Discount Double-Dipping
October 30, 2024
FDA Didn't Flub Approval In Orphan Drug Case, DC Court Says
October 18, 2024
Oklahoma Brings Title X Funding Cut Fight To Justices
October 11, 2024
Feds Target Ill. Hospital CEO As $19M Theft Probe Widens
October 11, 2024
Quinn Emanuel Gets Trimmed $92M Fee In ACA Cases
September 30, 2024
Takeda End Payors, Direct Buyers Win Antitrust Class Cert.
September 30, 2024
Bristol-Myers Beats Celgene Investors' Drug Delay Suit
September 27, 2024
9th Circ. Says Stem Cell Treatment Not Exempt From FDA Rule
August 30, 2024
McKesson, Others To Pay Benefit Plans $300M In Opioid Deal
August 23, 2024
NY Can't Sue Groups Over Abortion 'Reversal' Ads, For Now